

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

**INSIDE INFORMATION
COMPLETION OF
THE PUBLIC ISSUANCE OF
THE FIRST TRANCHE OF 2025 CORPORATE BONDS
IN THE PRC**

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of China Resources Pharmaceutical Group Limited (the “**Company**”) is pleased to announce that China Resources Pharmaceutical Holdings Company Limited (華潤醫藥控股有限公司) (“**CR Pharmaceutical Holdings**”), a wholly-owned subsidiary of the Company, has issued the first tranche of corporate bonds in the People’s Republic of China (the “**PRC**”) (the “**2025 Corporate Bonds**”) pursuant to the approval from the China Securities Regulatory Commission (Zheng Jian Xu Ke [2025] No. 1457) approving the public issuance of corporate bonds by CR Pharmaceutical Holdings to qualified investors in the PRC in an aggregate principal amount of no more than RMB10 billion.

The Board is pleased to announce that the first tranche of the 2025 Corporate Bonds has been issued in a principal amount of RMB1.1 billion with a term of three years and a coupon rate of 1.82% per annum.

The net proceeds raised from the issuance of the first tranche of the 2025 Corporate Bonds will be used for production expenditures, including repayment of corporate debts, replenishment of working capital, project development and operation expenditures, investments related to scientific and technological innovations, and other purposes in compliance with applicable laws and regulations.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 21 October 2025

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive director of the Company; Mr. Cheng Jie and Mr. Liu Changan as executive directors of the Company; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive directors of the Company and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive directors of the Company.